Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brent Woodson

Pulmonary Disease Grand Junction, CO Doctor of Osteopathy

NPI 1710133491 CMS profile 1095398

2373 G Rd Ste 160, Grand Junction, CO 81505

Open in the dashboard

General payments

$5,960

256 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brent Woodson of Grand Junction, CO is reported in the CMS Open Payments database as having received $5,960 across 256 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $648 40
2024 General $404 15
2023 General $14 1
2022 General $567 20
2021 General $1,046 55
2020 General $1,158 55
2019 General $2,123 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brent Woodson
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Brent Woodson were reported at $648. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Brent Woodson Pulmonary Disease median Middle half National median
2019 $2,123 $377 $109–$1,340 $163
2020 $1,158 $230 $56–$907 $114
2021 $1,046 $269 $68–$1,072 $132
2022 $567 $390 $100–$1,457 $149
2023 $14 $419 $114–$1,659 $160
2024 $404 $476 $123–$1,818 $164
2025 $648 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,735 44 payments
  2. Actelion Pharmaceuticals US, Inc. $741 34 payments
  3. GlaxoSmithKline, LLC. $577 29 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $520 25 payments
  5. Insmed, Inc. $366 22 payments
  6. United Therapeutics Corporation $226 13 payments
  7. Grifols USA, LLC $180 9 payments
  8. Genzyme Corporation $155 7 payments
  9. Pulmonx Corporation $147 3 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $133 6 payments
  11. Other $1,179 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,761 246 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $900 1 payment
  3. Education $299 9 payments
Products named General payments · program years 2019–2025
  1. SYMBICORT $1,083 12 payments
  2. OPSUMIT $600 29 payments
  3. UPTRAVI $574 26 payments
  4. TRELEGY ELLIPTA $439 22 payments
  5. Arikayce $366 22 payments
  6. SPIRIVA RESPIMAT $321 16 payments
  7. BREZTRI $222 9 payments
  8. TYVASO $159 9 payments
  9. DUPIXENT $157 4 payments
  10. ORENITRAM $154 9 payments
  11. Other $3,180 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,497

Median for Pulmonary Disease: 936

Drug cost

$870,778

Median for Pulmonary Disease: $487,987

Branded share of claims

86.8%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 286 $224,256
Adempas Riociguat Brand 13 $140,852
Fasenra Pen Benralizumab Brand 20 $109,252
Spiriva Respimat Tiotropium Bromide Brand 141 $98,414
Breo Ellipta Fluticasone/Vilanterol Brand 114 $73,088
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 90 $62,156
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 61 $51,292
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 44 $24,176
Symbicort Budesonide/Formoterol Fumarate Brand 56 $18,522
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 72 $11,419

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$100,983

Of which drugs: $4,143

Medicare patients

784

Average age 75

Services billed

1,490

410 women, 374 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
COPD 55%
Arthritis 49%
Ischemic heart disease 34%
Heart failure 28%
Depression 26%
Atrial fibrillation 25%
Chronic kidney disease 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 14 14 $4,006

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $92
$92 61 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $39
$39 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $38
$38 286 —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $35
$35 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record